Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

October 10, 2019

Despite criticism, FDA is doing what is right by rare cancer patients

On October 1, the first-ever Rare Cancer Day, an awareness day highlighting the challenges people living with rare cancers face and emphasizing the importance of early diagnosis, was marked by thousands nationwide. Cancer is not a singular disease but, rather, many diseases, of which several are rare. One in 5...
More Posts

Recent Posts

No Results With Current Filter Choices

8th Blueprint for Breakthrough: Validating Real-World Endpoints for an Evolving Regulatory Landscape

  "Real-World Evidence is already here." - Ned Sharpless, Acting FDA Commissioner On September 18, 2019, Friends of Cancer Research (Friends) and Alexandria Real Estate Equities, Inc. hosted a meeting to present data from the Real-World Evidence (RWE) Pilot 2.0, building on the Friends RWE Pilot 1.0. The meeting focused on the...

Real-World Evidence Roundtable

Friends of Cancer Research (Friends) convened a roundtable meeting on February 6, 2019, to identify key challenges and next steps to further characterize how real-world evidence (RWE) can fill evidence gaps about the performance of approved agents used in the real-world setting, including in populations that may not have been...

Designing the Future of Cell Therapies

“Patients are waiting. These therapies are potentially curative. They’re important for the field.” - Ellen Sigal   On May 17, 2019, Friends of Cancer Research (Friends) and the Parker Institute for Cancer Immunotherapy (PICI) held a public meeting on “Designing the Future of Cell Therapies” to explore forward-looking opportunities in the cell...

22nd Annual Cancer Leadership Awards Reception

This year's awardees at the 22nd Annual Cancer Leadership Awards Reception From L-R: Dr. Anthony Fauci, Dr. Richard Klausner September 21, 2018The Hay-Adams800 16th St NW, Washington, DC 20006   On September 21, 2018, Friends of Cancer Research (Friends) hosted the 22nd Annual Cancer Leadership Awards Reception. The yearly event brings together leaders in...

A Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine

  Next-generation sequencing (NGS) is becoming a commonly used tool in cancer treatment. Transparency regarding the clinical performance and utility of different NGS-based tests available will aid in clinical decision-making and facilitate improvements in patient care.  The 7th Annual Blueprint for Breakthrough Forum, held by Friends of Cancer Research (Friends) and...

The Future Use of Real-World Evidence

  Significant progress has been made in data collection efforts to support use of real-world evidence (RWE) in regulatory settings; however challenges remain, chiefly with combining, organizing, and analyzing data from various information sources. On July 10th, Friends of Cancer Research (Friends) hosted a meeting to present data from a pilot...

A Plea to Make Cancer Clinical Trials More Patient Friendly

Jim Omel is a myeloma patient and a cancer research advocate. He spoke at the 2017 Friends of Cancer Research Annual Meeting and was an author of the panel 2 whitepaper, Data Generation to Support Cross-Labeling of Indications for Combination Products. Below are his abridged remarks from the meeting. To...
first
prev
1
2
next
last
Back to Top